To treat patients with active infection, ViraCyte has developed the “ready to administer” Viralym series of products (Viralym-A, Viralym-B, Viralym-C, and Viralym-M). All Viralym products are initially obtained from highly screened donors, whose T cells are expanded, educated, frozen, and stored for use when needed. Our manufacturing processes do not alter the genetic make-up of the T cells, nor do they expose T cells to the actual viruses. Instead, we use natural immune stimulant proteins combined with non-harmful fragments of the virus, much like those that could be used for traditional immunization. ViraCyte’s proprietary manufacturing processes allow hundreds of patients to be treated from a single donation; and ViraCyte’s proprietary CytoMatch™ algorithm enables a small panel of donors to be able to treat approximately 95% of all HSCT patients who need Viralym products.